

ELEVATE EXCHANGE

Formulary Updates to Elevate Exchange Plans
(Bronze HDHP/Standard,
Silver Select/Standard,
Gold Select/Standard)

P&T/Formulary Committee Actions
2Q2021 (Effective July 1, 2021)

Formulary Actions Effective: 07/01/2021														
Drug Attributes							Formulary Status		Utilization Management		Rationale of Changes			
							Marketplace (HIEX)		Marketplace (HIEX)					
Category	Brand Name	Generic Name	Strength	Dosage Form	Route	Brand Status	Current Status	Action	Current Status	Action	COMMERCIAL	Optional Benefit Exclusion	Optional Non-Essential Exclusion (HIEX)	Client Communication - HIEX
ANTICONVULSANTS	ELEPSIA XR	LEVETIRACETAM	1000 MG	TAB ER 24H	ORAL	SSB	3	S=3	AGE QL	A=ST S=AGE S=QL	Low Net Cost Strategy			ST: TRIAL OF GENERIC LEVETIRACETAM ER IN THE PAST 120 DAYS
ANTICONVULSANTS	ELEPSIA XR	LEVETIRACETAM	1500 MG	TAB ER 24H	ORAL	SSB	3	S=3	AGE QL	A=ST S=AGE S=QL	Low Net Cost Strategy			ST: TRIAL OF GENERIC LEVETIRACETAM ER IN THE PAST 120 DAYS
ASTHMA AND COPD	PROAIR RESPICLICK	ALBUTEROL SULFATE	90 MCG	AER POW BA	INHALATION	SSB	2	S=2	NONE	A=ST	Low Net Cost Strategy			ST: TRIAL OF GENERIC ALBUTEROL SULFATE 90 MCG HFA INHALER IN THE LAST 120 DAYS
ASTHMA AND COPD	PROAIR DIGIHALER	ALBUTEROL SULFATE	90 MCG	AER PW BAS	INHALATION	SSB	3	S=3	NONE	A=ST	Low Net Cost Strategy			ST: TRIAL OF GENERIC ALBUTEROL SULFATE 90 MCG HFA INHALER IN THE LAST 120 DAYS
ASTHMA AND COPD	XOLAIR	OMALIZUMAB	150 MG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
ASTHMA AND COPD	XOLAIR	OMALIZUMAB	150 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ASTHMA AND COPD	XOLAIR	OMALIZUMAB	75MG/0.5ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
AUTONOMIC NERVOUS SYSTEM DISORDERS	MEMANTINE HCL ER	MEMANTINE HCL	14 MG	CAP SPR 24	ORAL	GENERIC	1	S=1	QL	A=ST S=QL	Low Net Cost Strategy			ST: TRIAL OF MEMANTINE IMMEDIATE RELEASE TABLETS IN THE PAST 120 DAYS
AUTONOMIC NERVOUS SYSTEM DISORDERS	MEMANTINE HCL ER	MEMANTINE HCL	21 MG	CAP SPR 24	ORAL	GENERIC	1	S=1	QL	A=ST S=QL	Low Net Cost Strategy			ST: TRIAL OF MEMANTINE IMMEDIATE RELEASE TABLETS IN THE PAST 120 DAYS
AUTONOMIC NERVOUS SYSTEM DISORDERS	MEMANTINE HCL ER	MEMANTINE HCL	28 MG	CAP SPR 24	ORAL	GENERIC	1	S=1	QL	A=ST S=QL	Low Net Cost Strategy			ST: TRIAL OF MEMANTINE IMMEDIATE RELEASE TABLETS IN THE PAST 120 DAYS
AUTONOMIC NERVOUS SYSTEM DISORDERS	MEMANTINE HCL ER	MEMANTINE HCL	7 MG	CAP SPR 24	ORAL	GENERIC	1	S=1	QL	A=ST S=QL	Low Net Cost Strategy			ST: TRIAL OF MEMANTINE IMMEDIATE RELEASE TABLETS IN THE PAST 120 DAYS
AUTONOMIC NERVOUS SYSTEM DISORDERS	NAMENDA XR	MEMANTINE HCL	7-14-21-28	CAP24 DSPK	ORAL	SSB	2	S=2	QL	A=ST S=QL	Low Net Cost Strategy			ST: TRIAL OF MEMANTINE IMMEDIATE RELEASE TABLETS IN THE PAST 120 DAYS
CARDIOVASCULAR DISEASE -HYPERTENSION	VENTAVIS	ILOPROST TROMETHAMINE	10 MCG/ML	AMPUL-NEB	INHALATION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	VENTAVIS	ILOPROST TROMETHAMINE	20 MCG/ML	AMPUL-NEB	INHALATION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	UPTRAVI	SELEXIPAG	1000 MCG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	UPTRAVI	SELEXIPAG	1200 MCG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	UPTRAVI	SELEXIPAG	1400 MCG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	UPTRAVI	SELEXIPAG	1600 MCG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	UPTRAVI	SELEXIPAG	200 MCG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	UPTRAVI	SELEXIPAG	200-800MCG	TAB DS PK	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	UPTRAVI	SELEXIPAG	400 MCG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	UPTRAVI	SELEXIPAG	600 MCG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	UPTRAVI	SELEXIPAG	800 MCG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	TYVASO	TREPROSTINIL	1.74MG/2.9	AMPUL-NEB	INHALATION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	ORENITRAM ER	TREPROSTINIL DIOLAMINE	0.125 MG	TABLET ER	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety/Trade Relations Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	ORENITRAM ER	TREPROSTINIL DIOLAMINE	0.25 MG	TABLET ER	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety/Trade Relations Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	ORENITRAM ER	TREPROSTINIL DIOLAMINE	1 MG	TABLET ER	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety/Trade Relations Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	ORENITRAM ER	TREPROSTINIL DIOLAMINE	2.5 MG	TABLET ER	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety/Trade Relations Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	ORENITRAM ER	TREPROSTINIL DIOLAMINE	5 MG	TABLET ER	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety/Trade Relations Strategy			
CARDIOVASCULAR DISEASE -HYPERTENSION	TREPROSTINIL	TREPROSTINIL SODIUM	1 MG/ML	VIAL	INJECTION	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy			

Formulary Actions Effective: 07/01/2021														
Drug Attributes							Formulary Status		Utilization Management		Rationale of Changes			
							Marketplace (HIE)		Marketplace (HIE)					
Category	Brand Name	Generic Name	Strength	Dosage Form	Route	Brand Status	Current Status	Action	Current Status	Action	COMMERCIAL	Optional Benefit Exclusion	Optional Non-Essential Exclusion (HIE)	Client Communication - HIE
CARDIOVASCULAR DISEASE - HYPERTENSION	TREPROSTINIL	TREPROSTINIL SODIUM	10 MG/ML	VIAL	INJECTION	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy			
CARDIOVASCULAR DISEASE - HYPERTENSION	TREPROSTINIL	TREPROSTINIL SODIUM	2.5 MG/ML	VIAL	INJECTION	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy			
CARDIOVASCULAR DISEASE - HYPERTENSION	TREPROSTINIL	TREPROSTINIL SODIUM	5 MG/ML	VIAL	INJECTION	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy			
CARDIOVASCULAR DISEASE - HYPERTENSION	TYVASO REFILL KIT	TREPROSTINIL/NEB ACCESSORIES	1.74MG/2.9	AMPUL-NEB	INHALATION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
CARDIOVASCULAR DISEASE - HYPERTENSION	TYVASO STARTER KIT	TREPROSTINIL/NEBULIZER/ACCESOR	1.74MG/2.9	AMPUL-NEB	INHALATION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
CARDIOVASCULAR DISEASE - LIPID IRREGULARITY	ROSZET	EZETIMIBE/ROSUVASTATIN CALCIUM	10 MG-10MG	TABLET	ORAL	SSB	3	S=3	QL	A=ST S=QL	Low Net Cost Strategy			ST: TRIAL OF ATORVASTATIN AND ROSUVASTATIN TABLETS IN THE LAST 365 DAYS
CARDIOVASCULAR DISEASE - LIPID IRREGULARITY	ROSZET	EZETIMIBE/ROSUVASTATIN CALCIUM	10 MG-20MG	TABLET	ORAL	SSB	3	S=3	QL	A=ST S=QL	Low Net Cost Strategy			ST: TRIAL OF ATORVASTATIN AND ROSUVASTATIN TABLETS IN THE LAST 365 DAYS
CARDIOVASCULAR DISEASE - LIPID IRREGULARITY	ROSZET	EZETIMIBE/ROSUVASTATIN CALCIUM	10 MG-40MG	TABLET	ORAL	SSB	3	S=3	QL	A=ST S=QL	Low Net Cost Strategy			ST: TRIAL OF ATORVASTATIN AND ROSUVASTATIN TABLETS IN THE LAST 365 DAYS
CARDIOVASCULAR DISEASE - LIPID IRREGULARITY	ROSZET	EZETIMIBE/ROSUVASTATIN CALCIUM	10 MG-5 MG	TABLET	ORAL	SSB	3	S=3	QL	A=ST S=QL	Low Net Cost Strategy			ST: TRIAL OF ATORVASTATIN AND ROSUVASTATIN TABLETS IN THE LAST 365 DAYS
DERMATOLOGY - ANTIINFLAMMATORY	SERNIVO	BETAMETHASONE DIPROPIONATE	0.05%	SPRAY/PUMP	TOPICAL	SSB	3	S=3	ST	C=ST	Low Net Cost Strategy			ST: TRIAL OF MOMETASONE 0.1% CREAM/SOLN OR TRIAMCINOLONE 0.1 % CREAM/OINT IN THE PAST 120 DAYS
DERMATOLOGY - ANTIINFLAMMATORY	CLOCORTOLONE PIVALATE	CLOCORTOLONE PIVALATE	0.10%	CREAM (G)	TOPICAL	GENERIC	1	S=1	NONE	A=ST	Low Net Cost Strategy			ST: TRIAL OF MOMETASONE 0.1% CREAM/SOLN OR TRIAMCINOLONE 0.1 % CREAM/OINT IN THE PAST 120 DAYS
DERMATOLOGY - ANTIINFLAMMATORY	VERDESO	DESONIDE	0.05%	FOAM	TOPICAL	SSB	3	S=3	NONE	A=ST	Low Net Cost Strategy			ST: TRIAL OF FLUOCINOLONE ACETONIDE 0.01% BODY OIL IN THE PAST 120 DAYS
DERMATOLOGY - ANTIINFLAMMATORY	FLURANDRENOLIDE	FLURANDRENOLIDE	0.05%	OINT. (G)	TOPICAL	GENERIC	1	S=1	NONE	A=ST	Low Net Cost Strategy			ST: TRIAL OF MOMETASONE 0.1% CREAM/SOLN OR TRIAMCINOLONE 0.1 % CREAM/OINT IN THE PAST 120 DAYS
DERMATOLOGY - ANTIINFLAMMATORY	ALA-SCALP	HYDROCORTISONE	2%	LOTION	TOPICAL	GENERIC	1	S=1	NONE	A=ST	Low Net Cost Strategy			ST: TRIAL OF GENERIC HYDROCORTISONE 2.5% LOTION IN THE PAST 120 DAYS
DERMATOLOGY - ANTIINFLAMMATORY	TEXACORT	HYDROCORTISONE	2.50%	SOLUTION	TOPICAL	SSB	2	S=2	NONE	A=ST	Low Net Cost Strategy			ST: TRIAL OF GENERIC HYDROCORTISONE 2.5% LOTION IN THE PAST 120 DAYS
DERMATOLOGY - ANTIINFLAMMATORY	HYDROCORTISONE VALERATE	HYDROCORTISONE VALERATE	0.20%	OINT. (G)	TOPICAL	GENERIC	1	S=1	NONE	A=ST	Low Net Cost Strategy			ST: TRIAL OF MOMETASONE 0.1% CREAM/SOLN OR TRIAMCINOLONE 0.1 % CREAM/OINT IN THE PAST 120 DAYS
DERMATOLOGY - MISCELLANEOUS	FLUOROURACIL	FLUOROURACIL	0.50%	CREAM (G)	TOPICAL	GENERIC	1	S=1	PA	C=PA	Clinical/Safety Strategy			
DERMATOLOGY - MISCELLANEOUS	EPIFOAM	HYDROCORTISONE/PRAMOXINE	1 %-1 %	FOAM	TOPICAL	SSB	3	S=3	NONE	A=ST	Low Net Cost Strategy			ST: TRIAL OF HYDROCORTISONE/PRAMOXINE 2.5%-1% CREAM IN THE PAST 120 DAYS
DERMATOLOGY - MISCELLANEOUS	PRAMOSONE	HYDROCORTISONE/PRAMOXINE	1 %-1 %	CREAM (G)	TOPICAL	SSB	2	S=2	NONE	A=ST	Low Net Cost Strategy			ST: TRIAL OF HYDROCORTISONE/PRAMOXINE 2.5%-1% CREAM IN THE PAST 120 DAYS
DERMATOLOGY - MISCELLANEOUS	PRAMOSONE	HYDROCORTISONE/PRAMOXINE	1 %-1 %	OINT. (G)	TOPICAL	SSB	2	S=2	NONE	A=ST	Low Net Cost Strategy			ST: TRIAL OF HYDROCORTISONE/PRAMOXINE 2.5%-1% CREAM IN THE PAST 120 DAYS
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	0.2MG/0.25	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	0.4MG/0.25	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	0.6MG/0.25	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	0.8MG/0.25	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	1.2MG/0.25	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	1.4MG/0.25	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	1.6MG/0.25	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	1.8MG/0.25	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	ZOMACTON	SOMATROPIN	10 MG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	ZOMACTON	SOMATROPIN	10 MG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	NUTROPIN AQ NUSPIN	SOMATROPIN	10 MG/2 ML	PEN INJECTR	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	NORDITROPIN FLEXPRO	SOMATROPIN	10MG/1.5ML	PEN INJECTR	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			

Formulary Actions Effective: 07/01/2021														
Drug Attributes							Formulary Status		Utilization Management		Rationale of Changes			
							Marketplace (HIEX)		Marketplace (HIEX)					
Category	Brand Name	Generic Name	Strength	Dosage Form	Route	Brand Status	Current Status	Action	Current Status	Action	COMMERCIAL	Optional Benefit Exclusion	Optional Non-Essential Exclusion (HIEX)	Client Communication - HIEX
ENDOCRINE DISORDER - OTHER	OMNITROPE	SOMATROPIN	10MG/1.5ML	CARTRIDGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	HUMATROPE	SOMATROPIN	12 MG	CARTRIDGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	12 MG/ML	CARTRIDGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	NORDITROPIN FLEXP	SOMATROPIN	15MG/1.5ML	PEN INJCTR	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	1MG/0.25ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	NUTROPIN AQ	SOMATROPIN	20 MG/2 ML	CARTRIDGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	NUTROPIN AQ NUSPIN	SOMATROPIN	20 MG/2 ML	PEN INJCTR	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	HUMATROPE	SOMATROPIN	24 MG	CARTRIDGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	2MG/0.25ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	NORDITROPIN FLEXP	SOMATROPIN	30 MG/3 ML	PEN INJCTR	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	HUMATROPE	SOMATROPIN	5 MG	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	SAIZEN	SOMATROPIN	5 MG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	ZOMACTON	SOMATROPIN	5 MG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	HUMATROPE	SOMATROPIN	5 MG	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	NORDITROPIN FLEXP	SOMATROPIN	5 MG/1.5ML	PEN INJCTR	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	OMNITROPE	SOMATROPIN	5 MG/1.5ML	CARTRIDGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	OMNITROPE	SOMATROPIN	5 MG/1.5ML	CARTRIDGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	NUTROPIN AQ NUSPIN	SOMATROPIN	5 MG/2 ML	PEN INJCTR	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	GENOTROPIN	SOMATROPIN	5 MG/ML	CARTRIDGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	OMNITROPE	SOMATROPIN	5.8 MG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	HUMATROPE	SOMATROPIN	6 MG	CARTRIDGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	SAIZEN	SOMATROPIN	8.8 MG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	SAIZEN-SAIENZPREP	SOMATROPIN	8.8MG/1.51	CARTRIDGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
ENDOCRINE DISORDER - OTHER	SAIZEN	SOMATROPIN	8.8MG/1.51	CARTRIDGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
HEMATOLOGICAL DISORDERS	SOLIRIS	ECULIZUMAB	300MG/30ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
HEMATOLOGICAL DISORDERS	ULTOMIRIS	RAVULIZUMAB-CWVZ	1100 MG/11	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
HEMATOLOGICAL DISORDERS	ULTOMIRIS	RAVULIZUMAB-CWVZ	300MG/30ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
HEMATOLOGICAL DISORDERS	ULTOMIRIS	RAVULIZUMAB-CWVZ	300MG/3ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
HEMATOLOGICAL DISORDERS	NPLATE	ROMIPLOSTIM	125 MCG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
HEMATOLOGICAL DISORDERS	NPLATE	ROMIPLOSTIM	250 MCG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
HEMATOLOGICAL DISORDERS	NPLATE	ROMIPLOSTIM	500 MCG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
INFECTIOUS DISEASE - FUNGAL	TOLSURA	ITRACONAZOLE	65 MG	CAP SD DSP	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy			
INFLAMMATORY DISEASE	HUMIRA(CF)	ADALIMUMAB	40MG/0.4ML	SYRINGEKIT	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
INFLAMMATORY DISEASE	HUMIRA(CF) PEN	ADALIMUMAB	40MG/0.4ML	PEN U KIT	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
INFLAMMATORY DISEASE	HUMIRA	ADALIMUMAB	40MG/0.8ML	SYRINGEKIT	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
INFLAMMATORY DISEASE	HUMIRA PEN	ADALIMUMAB	40MG/0.8ML	PEN U KIT	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
INFLAMMATORY DISEASE	HUMIRA(CF) PEN	ADALIMUMAB	80MG/0.8ML	PEN U KIT	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
INFLAMMATORY DISEASE	GEL-ONE	HYALURONATE SOD, CROSS-LINKED	30 MG/3 ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	HYALGAN	HYALURONATE SODIUM	10 MG/ML	VIAL	INTRAARTIC	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		

Formulary Actions Effective: 07/01/2021														
Drug Attributes							Formulary Status		Utilization Management		Rationale of Changes			
							Marketplace (HIEX)		Marketplace (HIEX)					
Category	Brand Name	Generic Name	Strength	Dosage Form	Route	Brand Status	Current Status	Action	Current Status	Action	COMMERCIAL	Optional Benefit Exclusion	Optional Non-Essential Exclusion (HIEX)	Client Communication - HIEX
INFLAMMATORY DISEASE	GELSYN-3	HYALURONATE SODIUM	16.8MG/2ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	ORHOVISC	HYALURONATE SODIUM	30 MG/2 ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	DUROLANE	HYALURONATE SODIUM, STABILIZED	60 MG/3 ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	MONOVISC	HYALURONATE SODIUM, STABILIZED	88 MG/4 ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	HYMOVIS	HYALURONATE, MOD., NON-CROSSLINK	24 MG/3 ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	SYNVISC	HYLAN G-F 20	16MG/2ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	SYNVISC-ONE	HYLAN G-F 20	48 MG/6 ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	ACTEMRA	TOCILIZUMAB	162 MG/0.9	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			
INFLAMMATORY DISEASE	ACTEMRA ACTPEN	TOCILIZUMAB	162 MG/0.9	PEN INJCTR	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			
LOWER GASTROINTESTINAL DISORDERS - OTHER	SUTAB	SOD SULF/POT CHLORIDE/MAG SULF	1.479 G	TABLET	ORAL	SSB	3	C=2	NONE	NONE	Trade Relations Strategy			
NEOPLASTIC DISEASE	YESCARTA	AXICABTAGENE CILOLEUCEL		PLAST. BAG	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	ZIRABEV	BEVACIZUMAB-BVZR	25 MG/ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	CABOMETYX	CABOZANTINIB S-MALATE	20 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
NEOPLASTIC DISEASE	CABOMETYX	CABOZANTINIB S-MALATE	40 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
NEOPLASTIC DISEASE	CABOMETYX	CABOZANTINIB S-MALATE	60 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
NEOPLASTIC DISEASE	LIBTAYO	CEMPIMUMAB-RWLC	350 MG/7ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	XALKORI	CRIZOTINIB	200 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
NEOPLASTIC DISEASE	XALKORI	CRIZOTINIB	250 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
NEOPLASTIC DISEASE	DARZALEX FASPRO	DARATUMUMAB-HYALLURONIDASE-FIHJ	1800-30000	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	VYXEOS	DAUNORUBICIN/CYTARABINE LIPOS	44MG-100MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	IMFINZI	DURVALUMAB	120 MG/2.4	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	IMFINZI	DURVALUMAB	500MG/10ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	ENHERTU	FAM-TRASTUZUMAB DERUXTECN-NXKI	100 MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	SARCLISA	ISATUXIMAB-IRFC	100 MG/5ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	SARCLISA	ISATUXIMAB-IRFC	500MG/25ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	LORBRENA	LORLATINIB	100 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
NEOPLASTIC DISEASE	LORBRENA	LORLATINIB	25 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
NEOPLASTIC DISEASE	OPDIVO	NIVOLUMAB	100MG/10ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	OPDIVO	NIVOLUMAB	240MG/24ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	OPDIVO	NIVOLUMAB	40 MG/4 ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	KEYTRUDA	PEMBROLIZUMAB	100 MG/4ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	ICLUSIG	PONATINIB HCL	15 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
NEOPLASTIC DISEASE	RITUXAN	RITUXIMAB	10 MG/ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	TRUXIMA	RITUXIMAB-ABBS	10 MG/ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	RIABNI	RITUXIMAB-ARRX	10 MG/ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	RUXIENCE	RITUXIMAB-PVVR	10 MG/ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	TRODELVY	SACITUZUMAB GOVITECAN-HZIV	180 MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
NEOPLASTIC DISEASE	COSELA	TRILACICLIB DIHYDROCHLORIDE	300 MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
OTHER DRUGS	FABRAZYME	AGALSIDASE BETA	35 MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
OTHER DRUGS	FABRAZYME	AGALSIDASE BETA	5 MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
OTHER DRUGS	BRONCHITOL	MANNITOL	40 MG	CAP W/DEV	INHALATION	SSB	4	S=4	QL	A=ST S=QL	Low Net Cost/Trade Relations Strategy			ST: TRIAL OF INHALED 7% SODIUM CHLORIDE SOLUTION IN THE PAST 120 DAYS.

Formulary Actions Effective: 07/01/2021														
Drug Attributes							Formulary Status		Utilization Management		Rationale of Changes			
							Marketplace (HIEX)		Marketplace (HIEX)					
Category	Brand Name	Generic Name	Strength	Dosage Form	Route	Brand Status	Current Status	Action	Current Status	Action	COMMERCIAL	Optional Benefit Exclusion	Optional Non-Essential Exclusion (HIEX)	Client Communication - HIEX
OTHER DRUGS	BOTOX	ONABOTULINUMTOXINA	100 UNIT	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
OTHER DRUGS	BOTOX	ONABOTULINUMTOXINA	200 UNIT	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
OTHER RESPIRATORY DISORDERS	OFEV	NINTEDANIB ESYLATE	100 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			
OTHER RESPIRATORY DISORDERS	OFEV	NINTEDANIB ESYLATE	150 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Trade Relations Strategy			
PAIN MANAGEMENT - ANALGESICS	VVEPTI	EPTINEZUMAB-JJMR	100 MG/ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	Non-Self Administered Drug (NSA)		
PAIN MANAGEMENT - ANALGESICS	AIMOVIG AUTOINJECTOR	ERENUMAB-AOOE	140 MG/ML	AUTO INJCT	SUBCUTANE.	SSB	2	S=2	PA	C=PA	Clinical/Safety Strategy			
PAIN MANAGEMENT - ANALGESICS	AIMOVIG AUTOINJECTOR	ERENUMAB-AOOE	70 MG/ML	AUTO INJCT	SUBCUTANE.	SSB	2	S=2	PA	C=PA	Clinical/Safety Strategy			
PAIN MANAGEMENT - ANALGESICS	AJOVY SYRINGE	FREMANEZUMAB-VFRM	225 MG/1.5	SYRINGE	SUBCUTANE.	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy			
PAIN MANAGEMENT - ANALGESICS	AJOVY AUTOINJECTOR	FREMANEZUMAB-VFRM	225 MG/1.5	AUTO INJCT	SUBCUTANE.	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy			
PAIN MANAGEMENT - ANALGESICS	EMGALITY PEN	GALCANEZUMAB-GNLM	120 MG/ML	PEN INJCTR	SUBCUTANE.	SSB	2	S=2	PA	C=PA	Clinical/Safety Strategy			
PAIN MANAGEMENT - ANALGESICS	EMGALITY SYRINGE	GALCANEZUMAB-GNLM	120 MG/ML	SYRINGE	SUBCUTANE.	SSB	2	S=2	PA	C=PA	Clinical/Safety Strategy			
PARKINSONS DISEASE	GOCOVRI	AMANTADINE HCL	137 MG	CAP ER 24H	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
PARKINSONS DISEASE	GOCOVRI	AMANTADINE HCL	68.5 MG	CAP ER 24H	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy			
WEIGHT REDUCTION	SAXENDA	LIRAGLUTIDE	3 MG/0.5ML	PEN INJCTR	SUBCUTANE.	SSB	2	S=2	PA	C=PA	Clinical/Safety Strategy	Antiobesity		
WEIGHT REDUCTION	CONTRAVE	NALTREXONE HCL/BUPROPION HCL	8 MG-90 MG	TABLET ER	ORAL	SSB	2	S=2	PA	C=PA	Clinical/Safety Strategy	Antiobesity		
WEIGHT REDUCTION	XENICAL	ORLISTAT	120 MG	CAPSULE	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	Antiobesity		
WEIGHT REDUCTION	QSYMIA	PHENTERMINE/TOPIRAMATE	11.25-69MG	CPMP 24HR	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	Antiobesity		
WEIGHT REDUCTION	QSYMIA	PHENTERMINE/TOPIRAMATE	15 MG-92MG	CPMP 24HR	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	Antiobesity		
WEIGHT REDUCTION	QSYMIA	PHENTERMINE/TOPIRAMATE	3.75-23 MG	CPMP 24HR	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	Antiobesity		
WEIGHT REDUCTION	QSYMIA	PHENTERMINE/TOPIRAMATE	7.5MG-46MG	CPMP 24HR	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	Antiobesity		

MedImpact Managed Formulary Actions

RATIONALE OF CHANGES

Trade Relations Strategy

Approach based on a financial review to deliver low net cost opportunities through pharmaceutical manufacture agreement strategies while taking into consideration the expected market share shift, future pipeline products, member impact and plan impact.

Low Net Cost Strategy

Delivering cost-efficient and clinically appropriate formulary content to meet the pharmacy benefit management needs of MedImpact clients; including appropriate development of preferred drug lists with consideration of low net cost strategies that includes MAC lists, non-pharmaceutical manufacture agreement strategies, and other cost management tools.

Clinical/Safety Strategy

Delivering cost-efficient and clinically appropriate formulary content to promote member safety and savings through the evaluation of scientific evidence, standards of practice, peer-reviewed medical literature, clinical practice guidelines, and guidance from the U.S. Food and Drug Administration (FDA)/Center for Disease Control (CDC).

Regulatory Update

Formulary/utilization management changes to comply with federal and/or state statutes, regulations, rules and policy requirements that pertain to the administration of the pharmacy benefit.

LEGEND

Note: The drug names listed are for reference purposes and denote action on the chemical entity unless otherwise specified. Where generic and brand products for a chemical entity co-exist, coverage and copayment for each will be a function of plan benefit design.

FORMULARY		UTILIZATION MANAGEMENT (UM)		OPTIONAL BENEFIT EXCLUSION
Formulary Status	Formulary Actions	UM Definition	UM Actions	Coverage for each category will be a function of plan benefit design. These products may be excluded on client benefits. Formulary and UM decisions only apply for clients who choose to provide coverage for these drug categories.
F = Formulary	C = Change	AGE = Age restriction	A = Add UM	Antiobesity
NF = Non-Formulary	S = Sustain	QL = Quantity Limit	D = Delete UM	Cosmetic Indications
E = Excluded		ST = Step Therapy	C = Change UM	Dietary Supplements and Non-Drug Products
NC = Not covered		CU = Concurrent Use edit	E = Excluded drug from formulary	Erectile Dysfunction
		PA = Prior Authorization	S = Sustain UM	Infertility
				Medical Foods: Dietary supplements, Enteral Feeding,
				Non-Self Administered Drug (NSA)
				Ostomy Supplies
				Class O = Over the Counter Products
				Class Q = Products that are neither drugs nor devices, such as dietary supplements (including prenatal and other vitamins), medical foods, herbal preparations, and bulk flavorings or colorants